PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of dermaendoLink to Publisher's site
 
Dermatoendocrinol. 2009 Nov-Dec; 1(6): 282–288.
PMCID: PMC3092567
Clinicopathological diversity of syringomas
A study on current clinical and histopathologic concepts
Cornelia S.L Müller,corresponding author Wolfgang Tilgen, and Claudia Pföhler
The Saarland University Hospital; Department of Dermatology; Homburg/Saar, Germany
corresponding authorCorresponding author.
Correspondence to: Cornelia S.L. Müller; Email: hacmue/at/uniklinikum-saarland.de
Received October 25, 2009; Accepted November 17, 2009.
Key words: syringoma, skin, adnexal neoplasms, histopathology, eccrine glands
Usually, syringomas display a wide spectrum of benign adnexal neoplasms derived from the intraepidermal part of eccrine sweat ducts.1 Women are more frequently affected than men. Syringomas mainly occur in the periorbital area, but also affect the scalp, forehead, neck, abdomen and extremities. A variety of clinical presentations of syringomas have been published, as well as cases associated with Down syndrome1 and familial syringoma. The eruptive occurrence of multiple syringomas in healthy persons has been reported rarely. We report a small case series of patients with syringomas, highlighting the different clinicopathologic manifestations and variations, and review the recent literature.
Histopathology findings and variants.
In general, syringomas present as symmetrical and well-delimited lesions located in the upper part of the dermis. Usually, there is no connection to the overlying epidermis. Syringomas are composed of single-to-double-layered epithelial cells with pale eosinophilic cytoplasm. Epithelial cells, forming nests, cords or tubules, with a typical comma-like tail characterize the neoplasm. Within the tubular lumen, PAS-positive eosinophilic material exists.1 Four clinical variants have been distinguished, following the proposal of Friedman and Butler in 1987, as follows:2 local, disseminated, syringoma associated with Down syndrome, and inherited forms. Thus, several additional entities of histomorphologic characteristic features have been described in the recent literature, as discussed in the following.
Eruptive syringomas are commonly very rare.3 In a review of the literature by Soler-Carrillo et al.3 Sixty-four cases (48 females and 16 males) were evaluated between 1872 and 1999; the ages ranged between 1 and 77 years. In general, women are more frequently affected with eruptive syringomas than men; in the patient cohort reviewed by Soler-Carrillo et al.,3 90% were females. In most cases, syringomas are asymptomatic small papules, preferentially located on the neck, trunk, axillae, shoulders, abdomen and pubic area. The initial clinical diagnosis differs in most cases, in contrast to the classical finding of eye lid syringomas, where histopathologic confirmation is not required for diagnosis. Hence, definitive diagnosis of an eruptive syringomas can only be verified by histologic examination (Figs. 2 and and77).
Figure 2
Figure 2
Extensive syringoma located in the vulva, causing severe pruritus (patient #2), H&E, ×100
Figure 7
Figure 7
Disseminated brownish papules at the chest and mammary of patient #3.
A unique syndrome that includes eruptive syringomas is the Nicolau-Balus syndrome, consisting of eruptive syringomas of the disseminated micropapular type, milium cysts and atrophoderma vermiculata.4 Seven reports on eruptive syringomas in patients with Down syndrome have been published.3,58 Further associations included urticaria pigmentosa, simulating milia and familial cases of eruptive syringomas.3
Although the definition of syringomas as benign neoplasms of the eccrine duct is widely accepted, the pathomechanisms and the genuine neoplastic character of eruptive syringomas are controversial. As reported in two cases by Requena et al.9 eruptive syringoma occur as a consequence of chronic inflammatory processes of the skin involving adnexal structures. The authors propose the term, “syringomatous dermatitis,” to outline the assumed underlying inflammatory reaction because the patients revealed eczematous dermatitis with residual lesions that could be histopathologically-diagnosed as an eccrine syringoma.9
Supporting this theory of an inflammatory impulse leading to proliferation of parts of the eccrine duct epithelium, there are several reports of syringomas in scarring alopecia (Fig. 1),1012 prurigo nodularis,13 and following radiation therapy;14 the inflammatory trigger has not been elucidated. Syringomatous changes have even been reported in melanocytic lesions, mostly as an incidental finding.1517 As presented in our case series, syringomatous proliferations are found in scarring alopecia of the scalp due to lichen planopilaris and in association with a lentiginous melanocytic proliferation (patients #1 and #4).
Figure 1
Figure 1
Reactive syringomatous proliferation in conjunction with scarring alopecia due to lichen planopilaris (patient #1), H&E, ×200
In the recent literature, the influence of hormones on the development of syringomas is discussed. This has been confirmed by the observation that syringomas have a much higher incidence in females and occur frequently before and around puberty.9 Further, pruritus is often associated with the menstrual cycle.18 The influence of hormones on the syringomatous reaction process is further supported by observations of an aggravation or manifestation of vulvar syringomas during pregnancy. 19,20 Vulvar syringomas most often present as multiple flesh-colored or brown papules on the labia majora of women in the third decade of life.21 Vulvar syringomas are thought to be a common cause of a mild-to-severe pruritus of the vulva, and therefore should be included in the differential diagnosis of vulvar pruritus.21 In case #2, syringomas were responsible for severe vulvar pruritus and also associated with chronic inflammatory bowel disease.
A very rare variant of syringomas is the so-called “milium-like” syringomas, first described in 1987 by Friedmann and Butler.2 Because of the syringomas unique clinical and histologic pattern, they must be distinguished from simple miliae. Histopathologically, milium-like syringomas present as a keratinous cyst opening on the skin surface with numerous epithelial strands in the surrounding dermal tissue. Typically for syringomas, ductal structures with eosinophilic amorphous material can be found.2 Only 31 cases of these syringoma variants have been reported in the literature. In one of these cases, an association between trisomy 21 and focal calcification was found.22
Very rare cases of syringomas with an atypical appearance have been described as unilateral lesions23,24 or simulating urticaria pigmentosa25,26 due to an increased content of mast cells. Furthermore, clear cell variants of syringomas have been described.27 Clear cell syringomas represent rare histologic variants of syringomas with a bright and clear cytoplasm of the ductal epithelial cells due to increased content of intracellular glycogen. Clear-cell syringomas are clinically indistinguishable from ordinary syringomas and are thought to be a cutaneous marker for diabetes mellitus.2830 None of the cases presented herein were milium-like or clear-cell-syringomas. In some cases, differential diagnosis between the so called plaque-type syringomas and microcystic adnexal carcinoma (MAC) of the skin can be very difficult, especially in superficial skin probes. MAC infiltrate much deeper into the dermis with regular involvement of subcutaneous structures and perineural and vascular-adventitial infiltration.31 In order to avoid unnecessary and even disfiguring surgery, histopathologic diagnosis of these plaque-type syringomas is mandatory.32
Most syringomas are harmless and benign, but of an aesthetically-disfiguring nature. Regression of lesions in adulthood has been observed, but is exceptional. Therapeutic efficacy is often frustrating, due to the slow growth and multicentric occurrence and the risk of scarring due to therapeutic procedures. Treatment modalities, such as topical or systemic retinoids, electrodissecation, laser ablation, cryosurgery, dermabrasion, electrocaustic therapy and chemical peelings have been attempted. However, all therapeutic options bear the risk of recurrence.3335 Recently, there have been reports of successful treatments of syringoma with topical atropine.36 Systematic approaches to all these therapeutic options are still lacking.
In summary, syringomas are benign neoplasms of the intraepidermal portion of the eccrine sweat duct and typically affect females in the facial regions, predominantly in the periorbital region. There have been a number of published clinical and histomorphologic variants (familial, milium-like, clear-cell, urticaria pigmentosa-like and vulvar), as well as many associated diseases and coincidental findings, such as Down syndrome or diabetes mellitus.
Nine patients with syringomas were referred to our department for evaluation between 2001 and 2008. All patients were females, with an age between 18 and 75 years (mean age, 50.5 years). The patient characteristics are summarized in Table 1.
Table 1
Table 1
Clinical data
In the cases presented, syringomas appeared as single or disseminated papules, yellow to brown in color, on the face in six of nine cases. Five of these patients had slight-to-severe pruritus. An eruptive occurrence was diagnosed in only one case. Of note, this 18-year-old female patient (#3) presented with a 3-year history of multiple skin lesions (Fig. 7). The disease started with few papules on the anterior neck and subsequent spread to the entire chest, abdomen, back and upper extremities. The submammary region was also affected. Syringomas were not present on the face, the palmoplantar region, or the lower extremities. The lesions were nearly asymptomatic, except for mild and occasional pruritus. Previous treatments with topical corticosteroids and phototherapy yielded no persistent improvement.
No laboratory abnormalities were detected in any cases. No family history of skin diseases or syrinogomas was reported. The physical examinations revealed multiple, disseminated, brown, isomorphic lesions, 1–5 mm in diameter, without follicular distribution. The Darier sign was negative. The remainder of the physical examination was without pathologic findings.
In one case, a syringomatous proliferation was observed coincidentally in a skin biopsy from the capillitium, associated with severe lichen planopilaris (#1; Fig. 1) in a further case (#4) as a dermal reaction pattern in an excision biopsy from a lentigo maligna. One patient had vulvar syringomas associated with severe vulvar pruritus (#2; Fig. 2) and a coincidental occurrence of Crohn's disease. In two cases, an association with psoriasis vulgaris (#7) and polymorphic light eruption (#9) could be observed. None of the patients suffered from diabetes mellitus or trisomy 21.
Dermatopathologic findings.
Skin biopsies of the patients presented were obtained either for diagnostic reasons or before laser ablation. All samples revealed a normal epidermis overlying a dermis filled with multiple cystic ducts and epithelial cords lined by one or two layers of polygonal epithelial cells with comma-like tails (Figs. 2 and and33). Mild fibroplasia of the surrounding stroma was observed (Fig. 4). The ductal lumens were filled with amorphous, periodic acid-Schiff (PAS)-positive material (Fig. 5). Routinely, haematoxylin-eosin staining was performed; special stains included the PAS reaction and elastica-van-Giessonstain, as well as immunohistochemical stains with cytokeratin markers (MNF116 and AE1/AE3) epithelial cords lined by one or two layers of polygonal epithelial cells with comma-like tails (Fig. 6).
Figure 4
Figure 4
Facial syringoma of patient #6 with fibrosing stroma reaction, H&E, ×100.
Figure 5
Figure 5
PAS-positive staining of amorphous material within the cystic luminas, PAS stain, ×200.
Figure 6
Figure 6
Epithelial cords lined by one or two layers of polygonal epithelial cells with comma-like tails, stained with cytokeratin marker AE1/AE3, ×100.
Syringomas occur frequently and predominantly affect women. These adnexal neoplasms are harmless and benign, but of an aesthetically-disfiguring nature since most often the face is affected. The histopathologic features are monomorphous with intriguing variations, e.g., clear-cell or milium-like variants. In the current literature, there is increasing evidence that the occurrence of eruptive syringomas or coincidental findings of these neoplasms in skin biopsies from scarring alopecia have to be discussed as an inflammatory dermal reaction pattern concerning the acrosyringium, the so-called syringomatous proliferation due to distinct inflammatory or hormonal stimuli.
As seen in the cases presented, most of the above-described variants of syringomas were found in the small patient cohort of our department. In agreement with recent reports, we also propose the term, reactive syringomatous proliferation, for most associations and coincidental findings of syringomas due to the absence of clinical features of a distinct clinicomorphologic entity.
Figure 3
Figure 3
Representative lesion of an eruptively disseminating syringomatosis (patient #3), H&E, ×100.
Acknowledgements
We thank Anne Kerber for excellent histological and immunohistological stainings.
1. Obaidat NA, Alsaad KO, Ghazarian D. Skin adnexal neoplasms—part 2: an approach to tumours of cutaneous sweat glands. J Clin Pathol. 2007;60:145–159. [PMC free article] [PubMed]
2. Friedman SJ, Butler DF. Syringoma presenting as milia. J Am Acad Dermatol. 1987;16:310–314. [PubMed]
3. Soler-Carrillo J, Estrach T, Mascaro JM. Eruptive syringoma: 27 new cases and review of the literature. J Eur Acad Dermatol Venereol. 2001;15:242–246. [PubMed]
4. Dupre A, Bonafe JL, Christol B. Syringomas as a causative factor for cicatricial alopecia. Arch Dermatol. 1981;117:315. [PubMed]
5. Carey AB, Park HK, Burke WA. Multiple eruptive syringomas associated with Down's syndrome. J Am Acad Dermatol. 1988;19:759–760. [PubMed]
6. Draznin M. Hereditary syringomas: a case report. Dermatol Online J. 2004;10:19. [PubMed]
7. Jacobs S, Grussendorf-Conen EI. Disseminated eruptive syringomas in Down syndrome. Hautarzt. 2004;55:70–72. [PubMed]
8. Schepis C, et al. Eruptive syringomas with calcium deposits in a young woman with Down's syndrome. Dermatology. 2001;203:345–347. [PubMed]
9. Guitart J, Rosenbaum MM, Requena L. ‘Eruptive syringoma’: a misnomer for a reactive eccrine gland ductal proliferation? J Cutan Pathol. 2003;30:202–205. [PubMed]
10. Barnhill RL, Goldberg B, Stenn KS. Proliferation of eccrine sweat ducts associated with alopecia areata. J Cutan Pathol. 1988;15:36–39. [PubMed]
11. Helm TN, et al. Occult syringoma associated with alopecia. Int J Dermatol. 1992;31:437–438. [PubMed]
12. Mehregan AH, Mehregan DA. Syringoma-like sweat duct proliferation in scalp alopecias. J Cutan Pathol. 1990;17:355–357. [PubMed]
13. Corredor F, Cohen PR, Tschen JA. Syringomatous changes of eccrine sweat ducts associated with prurigo nodularis. Am J Dermatopathol. 1998;20:296–301. [PubMed]
14. Yoshii N, et al. Syringoma-like eccrine sweat duct proliferation induced by radiation. J Dermatol. 2006;33:36–39. [PubMed]
15. Bhawan J, Malhotra R. Simultaneous occurrence of intradermal nevus and syringoma. Cutis. 1983;31:669–672. [PubMed]
16. Malhotra R, Bhawan J, Stadecker M. Association of syringoma and intradermal nevus. Int J Dermatol. 1986;25:397. [PubMed]
17. Nogita T, Kawashima M. Subclinical syringoma coexisting with nevocellular nevus on the vulva. J Dermatol. 1993;20:188–189. [PubMed]
18. Wallace ML, Smoller BR. Progesterone receptor positivity supports hormonal control of syringomas. J Cutan Pathol. 1995;22:442–445. [PubMed]
19. Turan C, et al. Vulvar syringoma exacerbated during pregnancy. Eur J Obstet Gynecol Reprod Biol. 1996;64:141–142. [PubMed]
20. Bal N, et al. Vulvar syringoma aggravated by pregnancy. Pathol Oncol Res. 2003;9:196–197. [PubMed]
21. Huang YH, et al. Vulvar syringoma: a clinicopathologic and immunohistologic study of 18 patients and results of treatment. J Am Acad Dermatol. 2003;48:735–739. [PubMed]
22. Seo SH, et al. A case of milium-like syringoma with focal calcification in Down syndrome. Br J Dermatol. 2007;157:612–614. [PubMed]
23. Wilms NA, Douglass MC. An unusual case of preponderantly right-sided syringomas. Arch Dermatol. 1981;117:308. [PubMed]
24. Yung CW, et al. Unilateral linear nevoidal syringoma. J Am Acad Dermatol. 1981;4:412–416. [PubMed]
25. Claudy AL. Adult-onset urticaria pigmentosa and eruptive syringomas. J Am Acad Dermatol. 1988;19:135. [PubMed]
26. Seifert HW. Association of disseminated syringoma and mast cells clinically resembling urticaria pigmentosa (author's transl) Z Hautkr. 1981;56:303–306. [PubMed]
27. Headington JT, Koski J, Murphy PJ. Clear cell glycogenosis in multiple syringomas. Description and enzyme histochemistry. Arch Dermatol. 1972;106:353–356. [PubMed]
28. Furue M, Hori Y, Nakabayashi Y. Clear-cell syringoma. Association with diabetes mellitus. Am J Dermatopathol. 1984;6:131–138. [PubMed]
29. Singh A, Mishra S. Clear cell syringoma—association with diabetes mellitus. Indian J Pathol Microbiol. 2005;48:356–357. [PubMed]
30. Krijnen RM, et al. Multiple clear-cell syringomas: a cutaneous marker for diabetes mellitus. Ned Tijdschr Geneeskd. 1999;143:1982–1983. [PubMed]
31. Henner MS, et al. Solitary syringoma. Report of five cases and clinicopathologic comparison with microcystic adnexal carcinoma of the skin. Am J Dermatopathol. 1995;17:465–470. [PubMed]
32. Suwattee P, et al. Plaque-type syringoma: two cases misdiagnosed as microcystic adnexal carcinoma. J Cutan Pathol. 2007 [PubMed]
33. Karam P, Benedetto AV. Intralesional electrodesiccation of syringomas. Dermatol Surg. 1997;23:921–924. [PubMed]
34. Mainitz M, Schmidt JB, Gebhart W. Response of multiple syringomas to isotretinoin. Acta Derm Venereol. 1986;66:51–55. [PubMed]
35. Metze D, Wigbels B, Hildebrand A. Familial syringoma: a rare clinical variant. Hautarzt. 2001;52:1045–1048. [PubMed]
36. Sanchez TS, et al. Eruptive pruritic syringomas: treatment with topical atropine. J Am Acad Dermatol. 2001;44:148–149. [PubMed]
Articles from Dermato-endocrinology are provided here courtesy of
Landes Bioscience